Phase I

Phase I. Represents the aspects of this Agreement that do not require more than 2 engineering days to implement (e.g. banner ads).

Phase I. Shall mean that portion of the FDA or equivalent foreign submission on which approval will be based which provides for the initial trials assessing the first introduction into humans of Licensed [***] Product with the purpose of determining human toxicity, metabolism, absorption, elimination and other pharmacological action as more fully defined in 21 C.F.R. Section 312.21(a) regardless whether these trials were conducted in or outside the United States.

Phase I. Means that part of the Building denoted as such on attached Exhibit A.

Phase I. Means the period of time between the date of this Agreement and December 31, 2003. Phase II means the period commencing on January 1, 2004. The above dates are target dates based on the parties current expectations and may be changed by mutual agreement of the parties. The details on the services to be performed during Phase I and Phase II are described in Section 3.2 below.

Phase I. Which is to extend for four (4) years following the Effective Date

Phase I. With respect to a clinical trial conducted pursuant to an IND, any controlled human clinical trial conducted in the United States as required under and pursuant to 21 C.F.R. §312.21(a), or, with respect to a jurisdiction other than the United States, a similar clinical study.